Medicenna Therapeutics (TSE:MDNA) Issues Quarterly Earnings Results

Medicenna Therapeutics (TSE:MDNA) posted its quarterly earnings data on Thursday. The company reported C($0.05) EPS for the quarter, FiscalAI reports. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%.

Medicenna Therapeutics Stock Performance

Shares of MDNA stock traded up C$0.01 during trading on Thursday, hitting C$0.41. The company’s stock had a trading volume of 61,179 shares, compared to its average volume of 108,080. The company has a market cap of C$34.62 million, a PE ratio of -2.77 and a beta of 2.89. The company has a current ratio of 2.68, a quick ratio of 4.65 and a debt-to-equity ratio of 3.30. The business has a fifty day moving average of C$0.51 and a 200-day moving average of C$0.75. Medicenna Therapeutics has a 52 week low of C$0.38 and a 52 week high of C$1.97.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.